XOMAinactive
XOMA Royalty Corp
Biopharma developer (SEC filing verified)
XOMA evidence brief
What we can confirm
- BioSniper Score:
- 7.3 / 10
- Lead Asset:
- ojemda (Approved)
What it means
The company data is ready for cross-source review; unsupported conclusions remain unknown.
What to watch
BioSniper Score: 7.3 / 10 · Lead Asset: ojemda (Approved)
BioSniper AIPage evidence connected
Prepared research question
What matters most for XOMA—catalysts, financial risk and supporting evidence?
Run cited research
Traceable citations · Unknowns marked
7.3/10
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Tracking 2 pipeline candidates for XOMA Royalty Corp.
Run XOMA Royalty Corp through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available XOMA Royalty Corp facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash RunwayN/A
Cash runway data unavailable
Financial HealthN/A
Financial health data unavailable
Pipeline Maturity10.0
Lead: Approved
Pipeline Breadth4.6
2 candidates
Catalyst MomentumN/A
No upcoming catalysts tracked
Insider SignalN/A
No insider transactions in the last 180 days
Pipeline
923 companies304,846 SEC filings22,720 clinical trials100% citation-verification pass rate (7d)How we verify →
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.